A. Patients over 40 years old rarely develop RA B. Women are more likely than men to develop RA C. Cigarette smoking has a neutral effect of the risk of developing RA D. Patients with chronic obstructive pulmonary disease are likely to develop RA

A. 0.1% B. 1% C. 3% D. 5%

A. Treat-to-target means using frequent assessments and therapy adjustments to reach a goal of low or no disease activity B. Treat-to-target means using biologic disease modifying antirheumatic drugs in all patients to achieve disease remission C. Treat-to-target means using aggressive therapy to achieve remission regardless of the safety profiles of the drugs used D. Treat-to-target means asking the patient what therapeutic target he/she wants to achieve and then using therapies to achieve only that goal

A. Vitamin D should be given to patients receiving methotrexate to prevent adverse effects B. Sulfasalazine is not used in rheumatoid arthritis patients C. The major toxicity associated with leflunomide is acute kidney injury D. Hydroxychloroquine does not usually cause ocular toxicity at clinically used doses

A. Approximately 50% of RA patients will achieve a 50% improvement in symptoms with any TNFi agent B. Only etanercept has been shown to halt joint destruction in RA patients C. Golimumab should be reserved for patients who have failed previous TNFi therapy due to is poor safety profile D. Only infliximab puts patients at risk of reactivation of tuberculosis

A. No relationship between serum trough infliximab levels and effectiveness of the drug has been found B. High levels of anti-infliximab antibodies have been associated with poor outcomes C. Serum peak and trough levels of infliximab must be used to calculate an appropriate dose D. Infliximab is the only tumor necrosis factor inhibitor for which serum trough levels can be measured

A. Studies suggest it is only effective is patients with a positive rheumatoid factor level B. It needs to be given monthly to achieve successful results in RA C. It may increase the risk of lymphomas in RA patients D. Infusion reactions are the most feared adverse effect with this drug

A. Increased risk of bacterial infections B. Reactivation of tuberculosis C. Intestinal perforation D. Dyslipidemia

A. It is more specific for certain JAK pathways than tofacitinib B. Head-to-head studies between baricitinib and tofacitinib have found no clinical differences between the 2 agents C. Baricitinib will be given subcutaneously, but tofacitinib is an oral tablet D. Baricitinib should only be used with methotrexate

A. Hepatitis A screening B. Herpes zoster vaccination C. Follow-up colonoscopy D. Repeat tuberculosis testing